Biotech / Pharma
VitriVax
Biotech / Pharma
VitriVax announced an $87 million Series C financing to advance its Lyme disease vaccine candidate into the clinic and expand its pipeline. F-Prime, NEA, RA Capital Management and Sanofi Ventures co-led the round, with participation from Eli Lilly and other existing investors.
Founded
Region
People